Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $25.00 price objective on the stock.

Other research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Benchmark boosted their price objective on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Humacyte currently has an average rating of “Buy” and an average price target of $13.71.

Humacyte Stock Performance

Shares of HUMA stock opened at $3.04 on Wednesday. The company has a market capitalization of $382.61 million, a P/E ratio of -2.27 and a beta of 1.30. The stock has a 50 day moving average price of $4.39 and a two-hundred day moving average price of $5.01. Humacyte has a fifty-two week low of $2.81 and a fifty-two week high of $9.97.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. Vontobel Holding Ltd. purchased a new stake in Humacyte in the fourth quarter valued at $50,000. Petros Family Wealth LLC acquired a new position in shares of Humacyte during the fourth quarter worth about $50,000. Syon Capital LLC purchased a new stake in shares of Humacyte in the 4th quarter valued at approximately $54,000. Brookstone Capital Management acquired a new stake in Humacyte in the fourth quarter valued at $56,000. Finally, ACT Wealth Management LLC purchased a new stake in Humacyte during the fourth quarter worth approximately $57,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.